ArticleVeterinary research communications2026
Construction of recombinant Lactococcus lactis expressing VP1 from duck hepatitis a virus types 1 and 3 and evaluation of its immune effect.
Article in Veterinary research communications, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In this study, VP1 genes from duck hepatitis A virus (DHAV) genotypes 1 (DHAV-1) and 3 (DHAV-3) were amplified through reverse transcription polymerase chain reaction (RT-PCR) by using viral RNA as the template. The amplified genes were cloned into the plasmid pNZ8149 through homologous recombination, yielding the recombinant plasmids pNZ8149-DHAV-1 VP1 and pNZ8149-DHAV-3 VP1. These plasmids were electroporated into competent L. lactis NZ3900 cells to generate the recombinant strains L. lactis pNZ8149-DHAV-1 VP1/NZ3900 and L. lactis pNZ8149-DHAV-3 VP1/NZ3900, respectively. Successful expression of VP1 in the recombinant L. lactis strains was confirmed through Western blot. One-day-old ducklings were orally immunized with the recombinant L. lactis strains (1 × 1011 CFU/200 μL) three times. Serum and intestinal mucosal scrapings were collected on days 5, 10, and 15 after immunization and on day 7 after viral challenge. Levels of specific antibodies and cytokines were measured in these samples. The results indicated that the recombinant L. lactis strains were successfully constructed and that they effectively expressed VP1. After oral immunization, antibody and cytokine levels in the serum and intestinal mucosa were significantly higher in immunized ducklings than in nonimmunized ducklings. These findings indicated that the recombinant L. lactis strains effectively stimulated systemic and mucosal immune responses, conferring significant immunoprotection against viral infection in ducklings.
Indexed as
Identifiers
41721885What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.